youtube_live
Q3 2026 earnings • released • EPS beat +257,92% • Revenue miss -13,60%
See resultschevron_right
GRAL:NASDAQ
Grail Inc
121,44 $
arrow_upward
+1,94%(+2,31) 1D
122,47 $
arrow_upward
+0,85% (+1,03)bedtimeAfter hours
Closed: 6 қар., 16:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRAL...
Open
122,00 $
High
129,70 $
Low
117,00 $
Mkt. cap
5,42 млрд
Avg. vol.
1,07 млн
Volume
756,38 м.
52-wk high
166,48 $
52-wk low
41,50 $
EPS
-9,75 $
Shares outstanding
44,67 млн
No. of employees
910
Open
122,00 $
High
129,70 $
Low
117,00 $
Mkt. cap
5,42 млрд
Avg. vol.
1,07 млн
Volume
756,38 м.
52-wk high
166,48 $
52-wk low
41,50 $
EPS
-9,75 $
Shares outstanding
44,67 млн
No. of employees
910
News stories
From web sources and news partners
Yahoo Finance Singapore
·
3 күн бұрын
Is GRAIL (GRAL) Fully Valued As Fresh Earnings Reignite Questions Over Galleri?
Yahoo Finance
·
3 күн бұрын
GRAIL Q3 Earnings Call Ties FDA Review to Pricing and Sales Growth
Profile
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021, GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023, EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.
Joshua Ofman is CEO. Wikipedia
About Grail Inc
CEO-
Employees910
Founded2015
HeadquartersMenlo Park, Калифорния, Америка Құрама Штаттары
SectorHealth Care
Industry-
Websitegrail.com